EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Transgenic Mouse Models of Alzheimer's Disease

Gregory A Elder, Miguel A Gama Sosa, Rita De Gasperi

Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · 2010-01 · 77 (1) · 69-81

DOI: 10.1002/msj.20159 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, online erschienen am 25.01.2010. Verfasst von Gregory A Elder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Service, James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA. gregory.elder@mssm.edu. Hauptthemen laut MEDLINE: Disease Models, Animal, Mice, Transgenic. Die Arbeit wurde bisher 284-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease is the most common cause of senile dementia in the United States and Europe. At present, there is no effective treatment. Given the disease's prevalence and poor prognosis, the development of animal models has been a high research priority. Transgenic modeling has been pursued on the basis of the amyloid hypothesis and has taken advantage of mutations in the amyloid precursor protein and the presenilins that cause familial forms of Alzheimer's disease. Modeling has been most aggressively pursued in mice, for which the techniques of genetic modification are well developed. Transgenic mouse models now exist that mimic a range of Alzheimer's disease–related pathologies. Although none of the models fully replicates the human disease, the models have contributed significant insights into the pathophysiology of β‐amyloid toxicity, particularly with respect to the effects of different β‐amyloid species and the possible pathogenic role of β‐amyloid oligomers. They have also been widely used in the preclinical testing of potential therapeutic modalities and have played a pivotal role in the development of immunotherapies for Alzheimer's disease that are currently in clinical trials. These models will, without a doubt, continue to play central roles in preclinical testing and be used as tools for developing insights into the biological basis of Alzheimer's disease. Mt Sinai J Med 77:69&–81, 2010. © 2010 Mount Sinai School of Medicine

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease Models, AnimalMice, TransgenicAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsHumansMiceMutationPresenilins

Substanzen

Amyloid beta-Protein PrecursorPresenilins

Autor:innen und Institutionen

  • Neurology Service, James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA. gregory.elder@mssm.edu

Förderung

  • BLRD VA
  • NIA NIH HHS

Zitieren

APA

Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010). Transgenic Mouse Models of Alzheimer's Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 77(1), 69-81. https://doi.org/10.1002/msj.20159

Vancouver

Elder GA, Gama Sosa MA, De Gasperi R. Transgenic Mouse Models of Alzheimer's Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 2010;77(1):69-81. doi:10.1002/msj.20159

BibTeX
@article{Elder2010,
  author = {Elder, Gregory A and Gama Sosa, Miguel A and De Gasperi, Rita},
  title = {Transgenic Mouse Models of Alzheimer's Disease},
  journal = {Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine},
  year = {2010},
  volume = {77},
  number = {1},
  pages = {69--81},
  doi = {10.1002/msj.20159}
}
Kostenlos starten →